28211499|t|The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis
28211499|a|The outcomes of studies analyzing the prognostic role of CTLA-4 in cancers are controversial. Therefore, the aim of our meta-analysis was to clarify the correlation between CTLA-4 expression and OS in different cancer cases. Relevant literature was searched using PubMed, EMBASE, Web of Science, and the Cochrane Library. The clinicopathological features, hazard ratio (HR) and 95% confidence intervals (CI) were collected from these studies and were analyzed using Stata version 12.0 software. The pooled HR values showed no significant correlation between CTLA-4 expression levels and OS in relation to tumors (HR: 1.24, 95% CI: 0.98-1.56, I2 = 71.7%, P = 0.000). Further subgroup analyses were conducted and categorized by experimental methods, CTLA-4 sources and cancer types. The survey showed a significant correlation (HR: 1.47, 95% CI: 1.14-1.89) between high expression of CTLA-4 and OS in the SNP subgroup, and subgroups analyzing by PCR (HR: 1.50, 95% CI: 1.20-1.86) and flow cytometry (HR: 2.76, 95% CI: 1.49-5.14). In addition, our analysis observed significant differences between patients and controls in in CTLA-4+ CD4+ lymphocytes, sur CTLA-4+ CD4+ lymphocytes, in CTLA-4+ CD8+ lymphocytes, and sur CTLA-4+ CD8+ lymphocytes. Knowledge of the effects of CTLA-4 could potentially be used to effectively guide appropriate prognosis and therapeutic strategies in cancer patients.
28211499	4	14	prognostic	T080	C1514475
28211499	24	56	cytotoxic T-lymphocyte antigen 4	T116,T129	C0111208
28211499	60	67	cancers	T191	C0006826
28211499	71	88	systematic review	T170	C1955832
28211499	93	106	meta-analysis	T062	C0920317
28211499	111	119	outcomes	T062	C0543472
28211499	131	140	analyzing	T062	C0936012
28211499	145	155	prognostic	T080	C1514475
28211499	164	170	CTLA-4	T116,T129	C0111208
28211499	174	181	cancers	T191	C0006826
28211499	227	240	meta-analysis	T062	C0920317
28211499	260	271	correlation	T080	C1707520
28211499	280	286	CTLA-4	T116,T129	C0111208
28211499	302	304	OS	T081	C4086681
28211499	318	324	cancer	T191	C0006826
28211499	341	351	literature	T170	C0023866
28211499	371	377	PubMed	T170	C1138432
28211499	379	385	EMBASE	T170	C0282574
28211499	387	401	Web of Science	T170	C0282574
28211499	411	427	Cochrane Library	T170	C0282574
28211499	433	461	clinicopathological features	T091	C0030667
28211499	463	475	hazard ratio	T081	C2985465
28211499	477	479	HR	T081	C2985465
28211499	489	509	confidence intervals	T081	C0009667
28211499	511	513	CI	T081	C0009667
28211499	558	566	analyzed	T062	C0936012
28211499	573	600	Stata version 12.0 software	T170	C0282574
28211499	606	612	pooled	T169	C2349200
28211499	613	615	HR	T081	C2985465
28211499	645	656	correlation	T080	C1707520
28211499	665	671	CTLA-4	T116,T129	C0111208
28211499	672	689	expression levels	T081	C3244092
28211499	694	696	OS	T081	C4086681
28211499	712	718	tumors	T191	C0027651
28211499	720	722	HR	T081	C2985465
28211499	734	736	CI	T081	C0009667
28211499	781	789	subgroup	T185	C1515021
28211499	790	798	analyses	T062	C0936012
28211499	833	853	experimental methods	T062	C0871738
28211499	855	861	CTLA-4	T116,T129	C0111208
28211499	874	886	cancer types	UnknownType	C0741888
28211499	892	898	survey	T170	C0038951
28211499	920	931	correlation	T080	C1707520
28211499	933	935	HR	T081	C2985465
28211499	947	949	CI	T081	C0009667
28211499	989	995	CTLA-4	T116,T129	C0111208
28211499	1000	1002	OS	T081	C4086681
28211499	1010	1013	SNP	T086	C0752046
28211499	1014	1022	subgroup	T185	C1515021
28211499	1028	1037	subgroups	T185	C1515021
28211499	1038	1047	analyzing	T062	C0936012
28211499	1051	1054	PCR	T063	C0032520
28211499	1056	1058	HR	T081	C2985465
28211499	1070	1072	CI	T081	C0009667
28211499	1089	1103	flow cytometry	T059	C0016263
28211499	1105	1107	HR	T081	C2985465
28211499	1119	1121	CI	T081	C0009667
28211499	1152	1160	analysis	T062	C0936012
28211499	1202	1210	patients	T101	C0030705
28211499	1215	1223	controls	T096	C0009932
28211499	1230	1237	CTLA-4+	T116,T129	C0111208
28211499	1238	1242	CD4+	T116,T129,T192	C0003323
28211499	1243	1254	lymphocytes	T025	C0024264
28211499	1260	1267	CTLA-4+	T116,T129	C0111208
28211499	1268	1272	CD4+	T116,T129,T192	C0003323
28211499	1273	1284	lymphocytes	T025	C0024264
28211499	1289	1296	CTLA-4+	T116,T129	C0111208
28211499	1297	1301	CD8+	T129	C0085358
28211499	1302	1313	lymphocytes	T025	C0024264
28211499	1323	1330	CTLA-4+	T116,T129	C0111208
28211499	1331	1335	CD8+	T129	C0085358
28211499	1336	1347	lymphocytes	T025	C0024264
28211499	1377	1383	CTLA-4	T116,T129	C0111208
28211499	1431	1442	appropriate	T080	C1548787
28211499	1443	1452	prognosis	T201	C3854082
28211499	1457	1479	therapeutic strategies	T061	C0087111
28211499	1483	1489	cancer	T191	C0006826
28211499	1490	1498	patients	T101	C0030705